Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Cancer Institute Hospital of Japanese Foundation for Cancer Research.
Koto-ku, Tokyo, Japan1 results ยท Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Esophageal Neoplasms, Head and Neck Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, biliary tract disorder, carcinoma, cholangiocarcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, esophageal adenocarcinoma, esophageal disorder, gallbladder carcinoma, gallbladder disorder, gallbladder neoplasm, gastric adenocarcinoma, gastric neoplasm, intestinal disorder, neoplasm, rectal disorder, stomach disorder | Active, not recruiting | Phase 2 | 2026-02-24 | NCT04430738 |